Navigation Links
Anti-pain agent shrinks oral cancers, leaves healthy tissues alone
Date:7/23/2014

SAN ANTONIO (July 22, 2014) Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found. The Health Science Center has claimed intellectual property on results of the study, which is described in the journal Oral Oncology.

Late diagnosis, low survival

Oral squamous cell carcinoma is the eighth most common cancer in the U.S. with 40,000 new cases and nearly 8,000 deaths reported annually. "These tumors develop primarily on the side of the tongue," said study first author Cara B. Gonzales, D.D.S., Ph.D., assistant professor of comprehensive dentistry and an investigator with the Cancer Therapy & Research Center at the UT Health Science Center at San Antonio. "Unfortunately, 60 percent of patients have large tumors before seeking help, and their five-year survival rate is as low as 30 percent."

Pain blocker and other properties

Capsazepine was developed to block TRPV1, a calcium channel found in pain-sensing neurons. When TRPV1 is activated, a "pain signal" is sent to the brain. Capsazepine may reduce oral cancer pain because it blocks tumor-secreted factors from stimulating TRPV1 on these neurons. Dr. Gonzales found that capsazepine also has anti-cancer activity that may be associated with its ability to increase oxidative damage in tumors. Enhanced oxidative stress leads to auto-destruction of tumor cells, the researchers theorize.

"Here's the beauty," Dr. Gonzales said. "Capsazepine kills cancers selectively, leaving normal tissues alone, and also acts on neurons to block pain, a desirable combination in a potential medication."

Hope for future: systemic administration

So far, only local administration of capsazepine, directly into the primary tumors, has been tested. But many patients with oral cancer have disease that has spread. "We would like to be able to deliver this therapy systemically to target metastatic disease," Dr. Gonzales said. "Our laboratory is working with the Center for Innovation in Drug Discovery, a partnership between the Health Science Center and UTSA, to develop novel drugs that are similar to capsazepine with improved efficacy for the purpose of systemic administration to treat tumors that are inaccessible to local injection or that have metastasized."

At-risk patients

Randal A. Otto, M.D., F.A.C.S., professor and chairman of the Department of Otolaryngology-Head & Neck Surgery in the School of Medicine, said: "These tumors, if identified and treated early, are definitely curable. Unfortunately, most patients present with advanced disease with the cancer involving critical structures. This markedly decreases the chance for cure and dramatically increases the risks associated with treatment. Anything that selectively attacks the tumor while not injuring the normal tissues can only help the patient."

Acknowledgments

This work is supported by American Cancer Society Mentored Research Scholar Grant MRSG-11-061-01-PCSM and in part by Clinical & Translational Science Award (CTSA) Grant UL1TR001120 and the National Cancer Institute P30 Grant CA054174 to the Cancer Therapy & Research Center at the UT Health Science Center at San Antonio.


'/>"/>

Contact: Will Sansom
sansom@uthscsa.edu
210-567-2579
University of Texas Health Science Center at San Antonio
Source:Eurekalert

Related medicine news :

1. Hematology Analyzers and Reagents Market Worth $3.13 Billion by 2019 - New Report by MarketsandMarkets
2. Tak Mak study in Cancer Cell maps decade of discovery to potential anticancer agent
3. Charitable Agents Launches Online Platform to Revolutionize Real Estate Transactions Through Commission-Based Donations
4. Boston Z Realty Expands Variety of Languages Spoken by Agents
5. Molecule regulates production of antibacterial agent used by immune cells
6. Tamoxifen-resistant breast cancer reversed when drug paired with anti-malaria agent
7. New tumor-targeting agent images and treats wide variety of cancers
8. ALTTO test of dual HER2 blockade finds single agent remains the gold standard
9. Water pipe smoking causes significant exposure to nicotine and cancer-causing agents
10. New agent may enhance effectiveness of radiotherapy
11. Danish social workers have become the moral agents of the state
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: